Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease in more than a decade.

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma giant’s pipeline and portfolio of cardio-pulmonary disease treatments.

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition of UK-based Verona Pharma for ~$10 billion.

For COPD patients with a nutritional goal to lose weight, some simple approaches can do a lot of good, Mosher noted, pointing to the importance of really focusing on portion sizes and the types of food they're putting on their plate.

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion for Verona Pharma and its potential blockbuster Ohtuvayre, a first-in-class treatment for chronic obstructive pulmonary disorder (COPD).

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with actionable improvement strategies.

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational campaign. The support will equip the Lung Association to work with rural partners and referral networks, plus local healthcare providers, to deliver services and education to COPD patients.

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively increasing symptom burden, exercise limitations, and frequent exacerbations,

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, marking the second biologic approved as an add-on maintenance treatment in this patient population.

A comprehensive meta-analysis of over 4.3 million adults shows e-cigarette use is associated with significantly higher odds of developing COPD. The risk persists even after adjusting for smoking history,

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in one healthcare system formulary led to increased healthcare utilization, a study showed, suggesting potential harm.